Cyclopharm Achieves Record Sales with US Expansion in 2024

Cyclopharm Limited ( (AU:CYC) ) just unveiled an update.

Cyclopharm Limited reported a record year in 2024, marked by the commencement of commercial sales in the United States following FDA approval. The company’s revenue reached $27.6 million, with Technegas sales contributing significantly. Despite a loss after tax of $13.2 million, Cyclopharm’s strategic expansion into the US market and its growing third-party distribution business are set to drive future growth. The company’s focus on expanding the use of Technegas for conditions beyond pulmonary embolism, such as COPD and asthma, indicates potential for accessing larger markets and achieving long-term growth.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited operates in the healthcare industry, specializing in nuclear medicine and medical imaging. The company is known for its Technegas product, which is used for diagnosing pulmonary embolism and other respiratory conditions. Cyclopharm has a significant market presence in 66 countries and is expanding its operations in the United States.

Average Trading Volume: 99,631

Technical Sentiment Signal: Sell

Current Market Cap: A$134.5M

For a thorough assessment of CYC stock, go to TipRanks’ Stock Analysis page.